Daehan New Pharm Co Ltd (054670)

Currency in KRW
7,200
0(0.00%)
Closed·

054670 Financial Summary

Key Ratios

P/E Ratio9.17
Price/Book0.93
Debt / Equity55.2%
Return on Equity10.5%
Dividend Yield1.39%
EBITDA22.76B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 914.02%
Dividend Yield
1.39%
Industry Median 0.93%
Annualised payout
100.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 12, 2025
EPS / Forecast
183.68 / --
Revenue / Forecast
51.85B / --
EPS Revisions
Last 90 days

FAQ

What were Daehan New Pharm's earnings for the latest quarter?

The Daehan New Pharm EPS (TTM) is 914.02. Daehan New Pharm reported sales of 51,854.78, net income of 2,578.05, and EPS of 183.68 for the latest quarter.

What was Daehan New Pharm's net income for the latest quarter?

Daehan New Pharm's net income for the latest quarter was 2,578.05.

How did Daehan New Pharm's performance compare year-over-year in the latest quarter?

The company's revenue moved from 50,979.02 in the previous quarter to 51,854.78 in the latest quarter, and net income moved from 2,683.06 to 2,578.05 compared to the previous quarter.

What is Daehan New Pharm's net profit margin on a TTM basis?

Daehan New Pharm's trailing twelve months (TTM) net profit margin is 7.65%.

How does Daehan New Pharm's debt to equity ratio compare to industry standards?

Daehan New Pharm's total debt-to-equity ratio is 55.20%.

What is Daehan New Pharm's return on investment on a TTM basis?

Daehan New Pharm's trailing twelve months (TTM) return on investment (ROI) is 10.50%.

Did Daehan New Pharm gain or lose cash last quarter?

In the latest quarter, Daehan New Pharm's net change in cash was -3,157.63 million.

What were Daehan New Pharm's total assets and liabilities in the latest quarter?

As of the latest quarter, Daehan New Pharm reported total assets of 233,900.70 million and total liabilities of 72,955.03 million.

How has Daehan New Pharm's total revenue grown this year?

Daehan New Pharm's total revenue was 50,979.02 in the previous quarter and 51,854.78 in the latest quarter.

What is Daehan New Pharm's gross margin on a TTM basis?

Daehan New Pharm's trailing twelve months (TTM) gross margin is 47.28%.

What was Daehan New Pharm's revenue per share for the latest quarter?

Daehan New Pharm's revenue per share for the latest quarter was 14,346.77.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.